Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
There has been progressively heightened interest in the development of targeted nanoparticles (NPs) for differential delivery and controlled release of drugs. Despite nearly three decades of research, approaches to reproducibly formulate targeted NPs with the optimal biophysicochemical properties have remained elusive. A central challenge has been defining the optimal interplay of parameters that confer molecular targeting, immune evasion, and drug release to overcome the physiological barriers in vivo . Here, we report a strategy for narrowly changing the biophysicochemical properties of NPs in a reproducible manner, thereby enabling systematic screening of optimally formulated drug-encapsulated targeted NPs. NPs were formulated by the self-assembly of an amphiphilic triblock copolymer composed of end-to-end linkage of poly(lactic-co-glycolic-acid) (PLGA), polyethyleneglycol (PEG), and the A10 aptamer (Apt), which binds to the prostate-specific membrane antigen (PSMA) on the surface of prostate cancer (PCa) cells, enabling, respectively, controlled drug release, “stealth” properties for immune evasion, and cell-specific targeting. Fine-tuning of NP size and drug release kinetics was further accomplished by controlling the copolymer composition. By using distinct ratios of PLGA- b -PEG- b -Apt triblock copolymer with PLGA- b -PEG diblock copolymer lacking the A10 Apt, we developed a series of targeted NPs with increasing Apt densities that inversely affected the amount of PEG exposure on NP surface and identified the narrow range of Apt density when the NPs were maximally targeted and maximally stealth, resulting in most efficient PCa cell uptake in vitro and in vivo . This approach may contribute to further development of targeted NPs as highly selective and effective therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Self-citationNanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Self-citation(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Self-citationFormulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Self-citationCell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Self-citationCatalytic activity of Au nanoparticles
Hvolbæk, B., Janssens, T. V. W., Clausen, B. S., Falsig, H., Christensen, C. H., & Nørskov, J. K. (2007) · Nano Today · doi:10.1016/s1748-0132(07)70113-5 · Cited by 887
Nanomedicine: Developing smarter therapeutic and diagnostic modalities☆
FAROKHZAD, O., & LANGER, R. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.011 · Cited by 800
Self-citationLupold, S. E., Hicke, B. J., Lin, Y. H., & Coffey, D. S. (2002) · PubMed · Cited by 566
Targeted nanoparticles for cancer therapy
Gu, F. X., Karnik, R., Wang, A. Z., Alexis, F., Levy-Nissenbaum, E., Hong, S., Langer, R. S., & Farokhzad, O. C. (2007) · Nano Today · doi:10.1016/s1748-0132(07)70083-x · Cited by 478
Self-citationTargeted Nanoparticles for Cancer Therapy
Reddy, G. S. N. (2021) · Journal of Bioanalysis & Biomedicine · Cited by 401
Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A
Leserman, L. D., Barbet, J., Kourilsky, F., & Weinstein, J. N. (1980) · Nature · doi:10.1038/288602a0 · Cited by 391
Hu, Y., Xie, J., Tong, Y. W., & Wang, C.-H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.11.028 · Cited by 351
Kubowicz, S., Baussard, J., Lutz, J., Thünemann, A. F., von Berlepsch, H., & Laschewsky, A. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200500584 · Cited by 299
Mosqueira, V. C. F., Legrand, P., Morgat, J.-L., Vert, M., Mysiakine, E., Gref, R., Devissaguet, J.-P., & Barratt, G. (2001) · Pharmaceutical Research · doi:10.1023/a:1012248721523 · Cited by 289
Aptamer:Toxin Conjugates that Specifically Target Prostate Tumor Cells
Chu, T. C., Marks, J. W., Lavery, L. A., Faulkner, S., Rosenblum, M. G., Ellington, A. D., & Levy, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4583 · Cited by 284
Sun, B., Ranganathan, B., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.09.038 · Cited by 274
Heath, T. D., Fraley, R. T., & Papahdjopoulos, D. (1980) · Science · doi:10.1126/science.7423203 · Cited by 237
Avgoustakis, K. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00224-2 · Cited by 211
Leamon, C. P., Cooper, S. R., & Hardee, G. E. (2003) · Bioconjugate Chemistry · doi:10.1021/bc020089t · Cited by 180
Self-Assembled Architectures from Biohybrid Triblock Copolymers
Reynhout, I. C., Cornelissen, J. J. L. M., & Nolte, R. J. M. (2007) · Journal of the American Chemical Society · doi:10.1021/ja066790f · Cited by 170
Labeling tumor cells with fluorescent nanocrystal–aptamer bioconjugates
Chu, T. C., Shieh, F., Lavery, L. A., Levy, M., Richards-Kortum, R., Korgel, B. A., & Ellington, A. D. (2006) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2005.12.015 · Cited by 160
Florence, A. T., & Halbert, G. (1985) · Physics in Technology · doi:10.1088/0305-4624/16/4/303 · Cited by 126
Chiu, S.-J., Liu, S., Perrotti, D., Marcucci, G., & Lee, R. J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.02.011 · Cited by 108
Popielarski, S. R., Pun, S. H., & Davis, M. E. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050113d · Cited by 83
Measurement of the Density of Polymeric Nanoparticulate Drug Carriers by Isopycnic Centrifugation
Vauthier, C., Schmidt, C., & Couvreur, P. (1999) · Journal of Nanoparticle Research · doi:10.1023/a:1010031605547 · Cited by 68
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationPEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Self-citationImpact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Self-citationKamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Self-citation
Metadata
- Authors
- Gu, F., Zhang, L., Teply, B. A., Mann, N., Wang, A., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-02-19
- Volume
- 105
- Issue
- 7
- Pages
- 2586-2591
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2088223764
- Cited by
- 715
- References
- 29
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.